FHA
HRMY icon

First Horizon Advisors’s Harmony Biosciences HRMY Stock Holding History

First Horizon Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34
Closed -$1.13K – 2408
2025
Q1 		$1.13K Hold
34
– – ﹤0.01% 2104
2024
Q4 		$1.17K Hold
34
– – ﹤0.01% 2076
2024
Q3 		$1.36K Hold
34
– – ﹤0.01% 2087
2024
Q2 		$1.02K Buy
+34
New +$1.02K ﹤0.01% 2114
2023
Q3 		– Sell
-609
Closed -$21.1K – 2447
2023
Q2 		$21.4K Sell
609
-125
-17% -$4.32K ﹤0.01% 1242
2023
Q1 		$24K Buy
734
+259
+55% +$11.8K ﹤0.01% 1197
2022
Q4 		$26.2K Buy
+475
New +$26.1K ﹤0.01% 1160

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Horizon Advisors's HRMY Position: Q2 2025 in Review

First Horizon Advisors sold out of Harmony Biosciences (HRMY) in Q2 2025, closing a stake of 34 shares — an estimated $1.13K sold.

First Horizon Advisors first reported a position in HRMY in Q4 2022 and held it in 7 quarters. The position peaked at $26.2K in Q4 2022. 279 funds tracked by Wall St. Rank hold HRMY as of Q2 2025.

  • First Horizon Advisors reported no remaining Harmony Biosciences position as of Q2 2025 after selling out during the quarter.
  • First Horizon Advisors sold 34 Harmony Biosciences shares in Q2 2025, an estimated $1.13K.
  • First Horizon Advisors first reported a position in Harmony Biosciences in Q4 2022 and held it in 7 quarters.
  • First Horizon Advisors's Harmony Biosciences position peaked at $26.2K in Q4 2022.
  • 279 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.